United Therapeutics Corporation Share Price

United Therapeutics Corporation Share Price

NASDAQ: UTHR | Large Cap
$598.16
+$11.75 (2.00%) Last updated on 29 Oct, 2026 | 19:56 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

United Therapeutics Corporation Stock Performance

Open
$593.14
Prev. Close
$586.41
Circuit Range
N/A
Day Range
$591.49 - $597.52
Year Range
$415.35 - $608.70
Volume
2,878
Average Traded
$594.98

United Therapeutics Corporation Share Price Today

As of 29 October 2026, United Therapeutics Corporation's share price is $598.16. The stock opened at $593.14, compared to its previous close of $586.41. During today's trading session, United Therapeutics Corporation's share price traded between $591.49 and $597.52, with an average price of $594.50. Over the past 52 weeks, the stock has recorded a high of $608.70 and a low of $415.35. In terms of performance, United Therapeutics Corporation's share price has risen by 4.64% over the last six months and is up 34.11% on a year-on-year basis.

United Therapeutics Corporation Share Price Chart

Line chart of the United Therapeutics Corporation price trend over the selected period. The price rose overall, ranging from 590.17 to 598.83, ending at 598.16.
$591.49$597.52
L
Show Current Price
H

United Therapeutics Corporation Stock Fundamentals & Key Indicators

Market Cap
$26.50B
PE Ratio (TTM)
19.19
Dividend Yield
0.00%
EPS (TTM)
$30.56
Revenue (TTM)
$3.18T
Return On Equity (TTM)
20.48%
Profit Margin
41.94%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-1.68%

United Therapeutics Corporation Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$799.50$790.20$781.50$783.30
Net Profit$338.70$364.30$274.90$333.00
Net Profit Margin42.36%46.10%35.18%42.51%
Income ChangeN/A7.56%-24.54%21.13%

United Therapeutics Corporation Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$1936.30$2327.50$2877.40$3182.70
Net Profit$727.30$984.80$1195.10$1334.70
Net Profit Margin37.56%42.31%41.53%41.94%
Income ChangeN/A35.40%21.35%11.68%

About United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

United Therapeutics Corporation Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$558.31
$597.52
+10.09%
Sep 2026
$513.98
$542.74
+2.75%
Aug 2026
$518.25
$528.19
+2.06%
Jul 2026
$542.63
$517.52
-4.46%
Jun 2026
$552.91
$541.70
-2.62%
May 2026
$566.16
$556.27
-2.69%
Apr 2026
$595.49
$571.64
-3.57%
Mar 2026
$511.55
$592.79
+17.59%
Feb 2026
$467.94
$504.12
+7.41%
Jan 2026
$489.06
$469.35
-3.62%
Dec 2025
$482.03
$487.00
+0.23%
Nov 2025
$441.24
$485.90
+8.94%

UTHR Share Price FAQs